Ambrosia Biosciences launches with $16M investment, Array chemistry team
Ambrosia Biosciences Inc., a recently formed drug-discovery company, has raised a $16 million Series A round and reunited a team of scientists that previously worked for Pfizer Inc.’s now-shuttered Boulder research and development operation.
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Biopharmaceutical company AmideBio LLC has received a $1.93 million grant from the federal government for…
-
BOULDER — Even with the COVID-10 pandemic several years in the rearview mirror, it remains…
-
Boulder Community Health this month became the first facility in Colorado to offer patients a…
-
Columbine Health Systems will host Dementia Week, a series of free events devoted to educating…
